Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say
10:32am, Thursday, 06'th Nov 2025
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with
Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3
09:30am, Thursday, 06'th Nov 2025
Xeris Biopharma (XERS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.06 per share a year ago.
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
07:00am, Thursday, 06'th Nov 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Moderate Buy” by Brokerages
01:40am, Friday, 31'st Oct 2025
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the stock, Market
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
07:30am, Thursday, 23'rd Oct 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice
01:00pm, Monday, 20'th Oct 2025
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?
10:16am, Monday, 20'th Oct 2025
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?
10:11am, Thursday, 16'th Oct 2025
Xeris Biopharma (XERS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increa
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 03'rd Oct 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy?
01:01pm, Friday, 03'rd Oct 2025
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
10:16am, Friday, 03'rd Oct 2025
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
01:01pm, Tuesday, 09'th Sep 2025
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy
10:03am, Friday, 05'th Sep 2025
Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady diversi
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
07:00am, Monday, 25'th Aug 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 12'th Aug 2025
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
